{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004232158973696.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.forsciint.2015.02.004"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0379073815000584?httpAccept=text/plain"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0379073815000584?httpAccept=text/xml"}},{"identifier":{"@type":"PMID","@value":"25703013"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Metabolism of the designer drug α-pyrrolidinobutiophenone (α-PBP) in humans: Identification and quantification of the phase I metabolites in urine"}],"description":[{"notation":[{"@value":"Urinary phase I metabolites of α-pyrrolidinobutiophenone (α-PBP) in humans were investigated by analyzing urine specimens obtained from drug abusers. Unequivocal identification and accurate quantification of major metabolites were realized using gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry with newly synthesized authentic standards. Two major phase I metabolic pathways were revealed: (1) reduction of the ketone group to 1-phenyl-2-(pyrrolidin-1-yl)butan-1-ol (OH-α-PBP, diastereomers) partly followed by conjugation to its glucuronide and (2) oxidation at the 2″-position of the pyrrolidine ring to α-(2″-oxo-pyrrolidino)butiophenone (2″-oxo-α-PBP) via the putative intermediate α-(2″-hydroxypyrrolidino)butiophenone (2″-OH-α-PBP). Of the phase I metabolites retaining the structural characteristics of the parent drug, OH-α-PBP was the most abundant in all specimens examined. Comparison of the phase I metabolism of α-PBP and α-pyrrolidinovalerophenone (α-PVP) suggested a relationship between the aliphatic side chain length and the metabolic pathways in α-pyrrolidinophenones: the shorter aliphatic side chain (1) led to more extensive metabolism via reduction of the ketone group than via the oxidation at the 2″-position of the pyrrolidine ring and (2) influenced the isomeric ratio of a pair of diastereomers."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004232158973704","@type":"Researcher","foaf:name":[{"@value":"Shuntaro Matsuta"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973705","@type":"Researcher","foaf:name":[{"@value":"Noriaki Shima"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973568","@type":"Researcher","foaf:name":[{"@value":"Hiroe Kamata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973698","@type":"Researcher","foaf:name":[{"@value":"Hidenao Kakehashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973702","@type":"Researcher","foaf:name":[{"@value":"Shihoko Nakano"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973570","@type":"Researcher","foaf:name":[{"@value":"Keiko Sasaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973569","@type":"Researcher","foaf:name":[{"@value":"Tooru Kamata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973706","@type":"Researcher","foaf:name":[{"@value":"Hiroshi Nishioka"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973700","@type":"Researcher","foaf:name":[{"@value":"Akihiro Miki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973696","@type":"Researcher","foaf:name":[{"@value":"Munehiro Katagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973697","@type":"Researcher","foaf:name":[{"@value":"Kei Zaitsu"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973701","@type":"Researcher","foaf:name":[{"@value":"Takako Sato"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973703","@type":"Researcher","foaf:name":[{"@value":"Hitoshi Tsuchihashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004232158973699","@type":"Researcher","foaf:name":[{"@value":"Koichi Suzuki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03790738"}],"prism:publicationName":[{"@value":"Forensic Science International"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2015-04","prism:volume":"249","prism:startingPage":"181","prism:endingPage":"188"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0379073815000584?httpAccept=text/plain"},{"@id":"https://api.elsevier.com/content/article/PII:S0379073815000584?httpAccept=text/xml"}],"createdAt":"2015-02-08","modifiedAt":"2018-09-25","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Propiophenones","dc:title":"Propiophenones"},{"@id":"https://cir.nii.ac.jp/all?q=Pyrrolidines","dc:title":"Pyrrolidines"},{"@id":"https://cir.nii.ac.jp/all?q=Gas%20Chromatography-Mass%20Spectrometry","dc:title":"Gas Chromatography-Mass Spectrometry"},{"@id":"https://cir.nii.ac.jp/all?q=Designer%20Drugs","dc:title":"Designer Drugs"},{"@id":"https://cir.nii.ac.jp/all?q=Tandem%20Mass%20Spectrometry","dc:title":"Tandem Mass Spectrometry"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Chromatography,%20Liquid","dc:title":"Chromatography, Liquid"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781825970432","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"15H02530"},{"@type":"JGN","@value":"JP15H02530"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15H02530/"}],"notation":[{"@language":"ja","@value":"最新質量分析計による体液中危険ドラッグの検出・同定法の開発及び学際的検討"},{"@language":"en","@value":"Application of novel mass spectrometric techniques for highly sensitive, specific and speedy identification of new psychoactive substances in human specimens"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231459164160","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Urinary excretion and metabolism of the newly encountered designer drug 3,4-dimethylmethcathinone in humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145801861760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Detection and Identification of Pyrovalerone and Its Hydroxylated Metabolite in the Rat"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168827094272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Dehydration‐fragmentation mechanism of cathinones and their metabolites in ESI‐CID"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619292742912","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinobutyrophenone (MPBP) in rat urine using gas chromatography–mass spectrometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095606071936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Studies on the metabolism of the α‐pyrrolidinophenone designer drug methylenedioxy‐pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC–MS and LC–high‐resolution MS and its detectability in urine by GC–MS"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848656389326976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Metabolism of the newly encountered designer drug α-pyrrolidinovalerophenone in humans: identification and quantitation of urinary metabolites"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520161272832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"New designer drug α‐pyrrolidinovalerophenone (PVP): studies on its metabolism and toxicological detection in rat urine using gas chromatographic/mass spectrometric techniques"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993504650496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Toxicology of Bath Salts: A Review of Synthetic Cathinones"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419215349504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Detection and Quantification of New Designer Drugs in Human Blood: Part 2 - Designer Cathinones"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371325001728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-α-pyrrolidinopropiophenone in urine using gas chromatography–mass spectrometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670318907729024","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) Analogues:  A Promising Class of Monoamine Uptake Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795419642624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Metabolism of the new designer drug α-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′-methyl-α-pyrrolidinopropiophenone (MPPP) studied in rat urine using gas chromatography-mass spectrometry"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205245160192","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Structural characterization of cathinone-type designer drugs by EI mass spectrometry"},{"@language":"ja","@value":"EI マススペクトル解析によるカチノン類の構造推定"},{"@language":"ja-Kana","@value":"EI マススペクトル カイセキ ニ ヨル カチノンルイ ノ コウゾウ スイテイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205245728128","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"1-Phenyl-2-(pyrrolidin-1-yl)pentan-1-one(α-PVP) の3種の類縁化合物のヒトにおける尿中代謝物及び代謝経路"},{"@language":"en","@value":"Urinary metabolites and metabolic pathways of three analogues of 1-phenyl-2-(pyrrolidine-1-yl)pentan-1-one (α-PVP) in humans"},{"@language":"ja-Kana","@value":"1-Phenyl-2-(pyrrolidin-1-yl) pentan-1-one (a-PVP)ノ 3シュ ノ ルイエン カゴウブツ ノ ヒト ニ オケル ニョウチュウ タイシャブツ オヨビ タイシャ ケイロ"},{"@value":"Urinary metabolites and metabolic pathways of three analogues of 1-phenyl-2-(pyrrolidine-1-yl)pentan-1-one (α-PVP) in humans"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679597999488","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Stereoselective reduction of acetohexamide in cytosol of rabbit liver."}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679603682560","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A Carbonyl Reductase-Catalyzing Reduction of N3-Phenacyluridine in Rabbit Liver."},{"@language":"ja-Kana","@value":"Carbonyl Reductase Catalyzing Reduction of N3 Phenacyluridine in Rabbit Liver"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.forsciint.2015.02.004"},{"@type":"KAKEN","@value":"PRODUCT-20407639"},{"@type":"OPENAIRE","@value":"doi_dedup___::7247333d71535fcf4f4754a64a8749c4"},{"@type":"CROSSREF","@value":"10.1002/jms.4538_references_DOI_VTeOb5HYbuzzt1Vn3sjDwo8T989"},{"@type":"CROSSREF","@value":"10.3408/jafst.735_references_DOI_VTeOb5HYbuzzt1Vn3sjDwo8T989"}]}